A Phase Ib/II, Open-label, Multicenter Study of Oral HDM201 in Combination With Oral LEE011 in Adult Patients With Liposarcoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs HDM 201 (Primary) ; Ribociclib (Primary)
- Indications Liposarcoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Novartis
- 05 Mar 2018 This trial has been suspended in Spain as per European Clinical Trials Database record.
- 07 Feb 2018 Planned End Date changed from 30 Dec 2018 to 31 Dec 2018.
- 07 Feb 2018 Planned primary completion date changed from 30 Dec 2018 to 31 Dec 2018.